CoA Therapeutics was founded in 2018 with the aim of harnessing advances in understanding of the CoA pathway to develop novel therapies for difficult to treat and rare genetic disorders. CoA Therapeutics’ approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock and Richard Lee at St. Jude Children’s Research Hospital in Memphis, Tennessee. CoA Therapeutics is led by veteran biotechnology executives whose sole objective is to partner with patients and physicians to bring effective therapies for PKAN and other diseases to market at the soonest possible opportunity.